A Phase 1, Open-Label, Safety, Reactogenicity, and Immunogenicity Trial of RVX-sCPD9, a Live-Attenuated SARS-CoV-2, as a Booster Vaccine, Via the Intranasal Route in Previously Vaccinated Adults

ingentiumby ingentium

In Vaccines News.

Publication date: Jul 16, 2026

This phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of RVX-sCPD9, given Intranasally (IN), as a booster dose to previously vaccinated healthy adults. The study is designed as a non-randomized, open-label, dose-escalation clinical trial evaluating four dose levels of RVX-sCPD9 administered IN (10^2, 10^3, 10^4, 5 x 10^4 FFU). A sample size of 80 participants (20 participants in each cohort). The primary objective is to evaluate the safety and reactogenicity of a single IN administration of 4 ascending dosages of RVX-sCPD9 in previously vaccinated healthy adults.

Concepts Keywords
Boost
Boster
Coronavirus
COVID
Intranasal
Next Generation
Phase 1
RVX-sCPD9
SARS-CoV-2
Vaccine

Semantics

Type Source Name
disease MESH amenorrhea
drug DRUGBANK Creatinine
drug DRUGBANK Alkaline Phosphatase
disease MESH ALP
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease MESH psychiatric
disease MESH alcohol abuse
disease MESH malignancy
disease MESH carcinoma in situ
disease MESH Bell’s palsy
disease MESH migraine headaches
disease MESH emergency
disease MESH epilepsy
disease MESH seizures
disease MESH encephalopathy
disease MESH focal neurologic deficits
disease MESH syndrome
disease MESH encephalomyelitis
disease MESH transverse myelitis
disease MESH stroke
disease MESH transient ischemic attack
disease MESH multiple sclerosis
disease MESH Parkinson’s disease
disease MESH amyotrophic lateral sclerosis
pathway KEGG Amyotrophic lateral sclerosis
disease MESH Creutzfeldt-Jakob disease
disease MESH Alzheimer’s disease
disease MESH asthma
pathway KEGG Asthma
disease MESH cardiovascular disease
disease MESH congestive heart failure
disease MESH cardiomyopathy
disease MESH ischemic heart disease
disease MESH myocarditis
disease MESH pericarditis
disease MESH cardiac arrhythmia
disease MESH autoimmune disease
disease MESH hypothyroidism
drug DRUGBANK Hepatitis B Vaccine (Recombinant)
disease MESH hepatitis C
pathway KEGG Hepatitis C
disease MESH infections
disease MESH hypersensitivity
disease MESH anaphylaxis
disease MESH urticaria
disease MESH angioedema
disease MESH Plan
drug DRUGBANK Fluticasone
drug DRUGBANK Medical Cannabis
disease MESH epistaxis
disease MESH rhinitis
disease MESH allergic rhinitis
disease MESH anosmia
disease MESH dysosmia
disease MESH Infectious Diseases

Original Article

(Visited 11 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *